Holen Sie sich die Stockscreener-App
34.33
3.56%
1.18
Handel nachbörslich:
34.27
-0.06
-0.17%
Schlusskurs vom Vortag:
$33.15
Offen:
$33.21
24-Stunden-Volumen:
565.13K
Relative Volume:
0.63
Marktkapitalisierung:
$2.74B
Einnahmen:
$517.15M
Nettoeinkommen (Verlust:
$66.35M
KGV:
41.80
EPS:
0.8212
Netto-Cashflow:
$126.63M
1W Leistung:
+1.57%
1M Leistung:
+4.22%
6M Leistung:
-6.53%
1J Leistung:
+6.81%
1-Tages-Spanne:
$32.72
$34.51
1-Wochen-Bereich:
$31.95
$34.63
52-Wochen-Spanne:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Firmenname
Veracyte Inc
Sektor
Branche
Telefon
(650) 243-6300
Adresse
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
34.33 | 2.74B | 517.15M | 66.35M | 126.63M | 0.8212 |
TMO
Thermo Fisher Scientific Inc
|
469.71 | 174.55B | 45.20B | 6.88B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.25 | 125.45B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
565.93 | 44.95B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.55 | 32.65B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
309.87 | 30.42B | 3.17B | 642.63M | 516.49M | 10.77 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | Jefferies | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Underweight |
| 2025-10-20 | Eingeleitet | Canaccord Genuity | Hold |
| 2025-03-20 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-16 | Eingeleitet | UBS | Buy |
| 2024-10-10 | Eingeleitet | Guggenheim | Buy |
| 2024-02-23 | Bestätigt | Needham | Buy |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-11-18 | Fortgesetzt | Goldman | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Outperform |
| 2021-02-18 | Fortgesetzt | Needham | Buy |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2019-07-31 | Eingeleitet | Lake Street | Buy |
| 2019-07-02 | Eingeleitet | Needham | Buy |
| 2018-11-29 | Herabstufung | Janney | Buy → Neutral |
| 2018-10-31 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-07 | Herabstufung | Janney | Buy → Neutral |
| 2017-11-07 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Fortgesetzt | BTIG Research | Buy |
| 2016-11-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-18 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-11 | Bestätigt | Leerink Partners | Outperform |
| 2013-11-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Veracyte Inc Aktie (VCYT) Neueste Nachrichten
Veracyte (VCYT) down 15.4% since last earnings report: Can it rebound? - MSN
Q3 2025 Veracyte Inc Earnings Call Transcript - GuruFocus
Q1 2025 Veracyte Inc Earnings Call Transcript - GuruFocus
Q2 2025 Veracyte Inc Earnings Call Transcript - GuruFocus
Veracyte Inc at Piper Sandler Healthcare Conference (Virtual)Pre-recorded Fireside Chat Transcript - GuruFocus
Veracyte Inc (VCYT) Stock Up 3.5% and Still Undervalued -- GF Sc - GuruFocus
Emerging Sub-Segments Transforming the Thyroid Cancer Diagnostics Market Landscape - openPR.com
VCYT Veracyte delivers triple digit Q4 2025 EPS beat and 16 percent annual revenue growth despite mild stock dip.EBITDA Margin - Cổng thông tin điện tử Tỉnh Sơn La
Veracyte (NASDAQ: VCYT) asks investors to back directors, auditor and larger equity plan - Stock Titan
Emerging Growth Patterns Driving Expansion in the Liquid Biopsy for Cancer Diagnostics Market - openPR.com
VCYT Maintained by Canaccord Genuity -- Price Target Lowered to $40 - GuruFocus
CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Cuts Target Price to $40 - Moomoo
Veracyte Price Target Cut to $40.00/Share From $43.00 by Canaccord Genuity - Moomoo
Veracyte (NASDAQ:VCYT) Given New $40.00 Price Target at Canaccord Genuity Group - MarketBeat
Is Veracyte (VCYT) Offering Value After Mixed Returns And Conflicting Valuation Signals - Yahoo Finance
Veracyte, Inc. (NASDAQ:VCYT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Assessing Veracyte (VCYT) Valuation After A Recent Share Price Rebound - Sahm
Sumitomo Mitsui Trust Group Inc. Sells 224,185 Shares of Veracyte, Inc. $VCYT - MarketBeat
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026 - BioSpace
Veracyte to Release Q1 2026 Results on May 5 - National Today
Veracyte to Release Q1 2026 Earnings on May 5 - National Today
Veracyte (NASDAQ: VCYT) awards 44,221 RSUs to Chief Dev and Tech Officer - Stock Titan
Jefferies Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $45 - 富途牛牛
Veracyte Inc (VCYT) Stock Up 4.3% and Still Undervalued -- GF Sc - GuruFocus
Jefferies initiates coverage of Veracyte (VCYT) with buy recommendation - MSN
VCYT Initiates Coverage by Jefferies -- Price Target Set at $45 - GuruFocus
Veracyte (NASDAQ:VCYT) Coverage Initiated at Jefferies Financial Group - MarketBeat
Jefferies Initiates Veracyte at Buy With $45 Price Target - marketscreener.com
Jefferies initiates Veracyte stock with buy on diagnostics growth - Investing.com UK
Jefferies initiates Veracyte stock with buy on diagnostics growth By Investing.com - Investing.com Canada
Veracyte | 4: Statement of changes in beneficial ownership of securities-Officer Wygant Jonathan - Moomoo
VCYT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Sentiment Watch: Can Veracyte Inc be the next market leaderPortfolio Gains Report & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Veracyte Inc (VCYT) Shares Down 4.29% on Apr 9 - GuruFocus
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte Stock Crosses Below 200-Day Moving Average - National Today
Veracyte (NASDAQ:VCYT) Stock Price Crosses Below 200 Day Moving AverageHere's Why - MarketBeat
Veracyte, Inc. (VCYT) Stock forecasts - Yahoo Finance UK
VCYT Technical Analysis & Stock Price Forecast - Intellectia AI
VCYT PE Ratio & Valuation, Is VCYT Overvalued - Intellectia AI
Veracyte Inc (NASDAQ:VCYT) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate - ChartMill
Emerging Growth Patterns Driving Rapid Expansion in the Oncology Molecular Diagnostics Market - openPR.com
Precision Trading with Veracyte Inc. (VCYT) Risk Zones - Stock Traders Daily
Veracyte (VCYT): Needham Reaffirms "Buy" Rating with $48 Price T - GuruFocus
Veracyte (NASDAQ:VCYT) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Needham reiterates Veracyte stock rating on bladder cancer test plans By Investing.com - Investing.com South Africa
Needham reiterates Veracyte stock rating on bladder cancer test plans - Investing.com
Veracyte, Inc. (VCYT) stock price, news, quote and history - uk.finance.yahoo.com
Finanzdaten der Veracyte Inc-Aktie (VCYT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):